<DOC>
	<DOC>NCT02871635</DOC>
	<brief_summary>Primary Objective: The primary objective of this trial is to compare the clinical efficacy of BI 695501 with EU-approved Humira® in patients with active Crohn's disease (CD). Secondary Objectives: The secondary objectives of this trial are to compare the efficacy and safety of BI 695501 with EU-approved Humira® across the induction and maintenance phases.</brief_summary>
	<brief_title>BI 695501 Versus Humira in Patients With Active Crohn's Disease: a Trial Comparing Efficacy, Endoscopic Improvement, Safety, and Immunogenicity</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Inclusion criteria: Males and females aged &gt;=18 and =&lt;80 years at Screening who have a diagnosis of moderate to severely active Crohn's Disease (CD), confirmed by endoscopy or radiologic evaluation, for more than 4 months with evidence of mucosal ulceration. Patients must have all of the following: Crohn's Disease Activity Index (CDAI) score of &gt;=220 and =&lt;450 A diagnosis of Crohn's Disease (CD) confirmed by ileocolonoscopy during Screening Endoscopic documentation of ulceration at Screening corresponding to a score of 2 or 3 in at least one of the five segments of the colon on the Ulcerated Surface subscore of the Simple Endoscopic Score for Crohn's Disease (SESCD) Antitumor necrosis factor (TNF) naïve patients or patients previously treated with infliximab or any other anti TNF agent (except adalimumab) who had initially responded and who meet one of the following criteria: Responded and developed secondary resistance due confirmed antiinfliximab antidrug antibody formation, which caused infliximab depletion Responded and became intolerant Further inclusion criteria apply Exclusion criteria: Patients with ulcerative colitis or indeterminate colitis Patients with symptomatic known obstructive strictures Surgical bowel resection performed within 6 months prior to Screening or planned resection at any time while enrolled in the trial Patients with an ostomy or ileoanal pouch Patients with short bowel syndrome Patients who have previously used infliximab and have never clinically responded Patients who have previously received treatment with adalimumab, or who have participated in an adalimumab or adalimumab biosimilar clinical trial, or are positive for antiadalimumab antibodies at baseline Further exclusion criteria apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>